Trial Profile
A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms AIN457A2324
- Sponsors Novartis Pharmaceuticals
- 04 Jan 2022 Primary endpoint has been met (Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set))as per Results published in the British Journal of Dermatology
- 04 Jan 2022 Results assessing efficacy, safety and tolerability of secukinumab published in the British Journal of Dermatology
- 11 May 2021 The study protocol amended to add active comparator: secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up) arm. The number of treatment arms increased from 2 to 3.